NCT07232732
A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity
Completed
PHASE1Ages 18–65InterventionalBasic scienceEli Lilly and Company
~120 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:LY3549492
At a glance
Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Measured over Baseline through end of the Follow-up Period (Week 10)
Conditions
Where it's being run
3 sites across 3 statesFlorida1
Texas1
Wisconsin1
Study leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Have a hemoglobin A1c level of less than 6.5 percent (%) at screening.
Have a body mass index (BMI) of 25.0 to 45.0 kilogram per square meter (kg/m²), inclusive, at screening
Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individual of childbearing potential (INOCBP) Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion
Have obesity induced by endocrine disorders such as Cushing's syndrome or Prader Willi syndrome.
Have any of the following conditions at screening,
supine systolic blood pressure of 160 millimeter of mercury (mmHg) or greater
supine diastolic blood pressure of 100 mmHg or greater, or
resting pulse rate of greater than 95 beats per minute (bpm) or less than 45 bpm. (Note: white-coat hypertension is excluded; therefore, if a repeated measurement of blood pressure after at least 5 minutes shows values within the range, the participant can be included).
Have had any of the following within 6-months prior to screening
myocardial infarction
unstable angina
coronary artery bypass graft
percutaneous coronary intervention. (Note: diagnostic angiograms are permitted)
transient ischemic attack
cerebrovascular accident or decompensated congestive heart failure, or
New York Health Association Class III or IV heart failure.
Have serum triglyceride of 5 millimoles per liter (mmol/L) or greater (442 milligrams per deciliter \[mg/dL\]) at screening
Have had any exposure to glucagon-like peptide-1 (GLP-1) analogs or other related compounds within the 3 months prior to screening
What this trial measures
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationBaseline through end of the Follow-up Period (Week 10)
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module